novo nordisk obesity drug

Novo Nordisk shares drop

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.

The Wall Street Journal · 3d

Novo Nordisk Stock Slides After Obesity Drug Trial Disappoints

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in rival Eli Lilly also sold off. Find out more:

STAT · 3d

Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that fell short of investors’ expectations.

16hon MSN

Altimmune to test obesity drug for alcohol use disorder and related health conditions

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

MedCity News4d

Novo Nordisk’s Next-Gen Obesity Drug Disappoints Again With Lower Than Expected Weight Loss

A next-generation Novo Nordisk metabolic disorder drug led to statistically significant weight loss in a pivotal test in participants with obesity and type 2 diabetes, results it says support ...

Pharmaceutical Technology2d

Viking strikes $150m deal to secure supply of obesity drug

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...

2don MSN

Roche secures Zealand obesity drug candidate for up to $5.3 billion

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results